Background and Objectives: Polycystic ovary syndrome (PCOS) and nonalcoholic fatty liver disease (NAFLD) commonly co-occur and are associated with insulin resistance, chronic inflammation, and metabolic and hormonal imbalances. Standard drug therapies can cause side effects, so safer and more effective alternatives are needed. This study evaluated whether daily curcumin supplementation could improve lipid, metabolic, hormonal, and liver-related parameters in women of reproductive age with both PCOS and NAFLD. Study Design and Participants: This was a double-blind, randomized, placebo-controlled clinical trial conducted at Arash General Women's Hospital. Ninety-four women of reproductive age diagnosed with PCOS and NAFLD were enrolled and randomly assigned to receive curcumin or placebo. Intervention: Participants in the intervention group received 1000 mg curcumin daily; the control group received 1000 mg placebo daily. The treatment period was 12 weeks. Measurements were taken at baseline and after 12 weeks. Key measurements: Anthropometric measurements, lipid profile (total cholesterol, LDL, HDL, triglycerides), fasting blood glucose, HbA1c, serum testosterone, anti-mullerian hormone (AMH), liver enzymes (AST, ALT, ALP), and liver ultrasound for degree of steatosis.
Age range
18 Years – 45 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Liver ultrasound view (gradient change)
Timeframe: Before the intervention and 48 hours after the end of the intervention
Body mass index (BMI)
Timeframe: Before the intervention and 48 hours after the end of the intervention
The level of low-density lipoprotein (LDL)
Timeframe: before the intervention and 48 hours after the intervention
The level of high-density lipoprotein (HDL)
Timeframe: before the intervention and 48 hours after the intervention
The level of triglyceride (TG)
Timeframe: before the intervention and 48 hours after the intervention
The level of cholesterol
Timeframe: before the intervention and 48 hours after the intervention
The level of alanine aminotransferase (ALT)
Timeframe: before the intervention and 48 hours after the intervention
The level aspartate aminotransferase (AST)
Timeframe: Before the intervention and 48 hours after the intervention
The level of alkaline phosphatase (ALP)
Timeframe: Before the intervention and 48 hours after the intervention